Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment

Current Opinion in HIV and AIDS

Volumn 10, Issue 5, 2015, Pages 369-373

  Cohn, Jennifer ^a,b   Roberts, Teri ^b   Amorosa, Valerianna ^a   LeMoine, Maud ^c   Hill, Andrew ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c ST MARY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Access; Diagnosis; Hepatitis C virus; Scale up; Simplification

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VIRUS RNA; UNCLASSIFIED DRUG; VIRUS RNA; HEPATITIS C ANTIGEN;

ANTIVIRAL THERAPY; DIAGNOSTIC TEST; HEPATITIS C; HEPATITIS C ANTIGEN TEST; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; BLOOD; DRUG MONITORING; GENOTYPING TECHNIQUE; HEPATITIS C, CHRONIC; PROCEDURES; TRENDS;

ANTIVIRAL AGENTS; DIAGNOSTIC TESTS, ROUTINE; DRUG MONITORING; GENOTYPING TECHNIQUES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; RNA, VIRAL;

EID: 84942912048     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000180     Document Type: Review

References (24)

1. WHO. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/in dex.html. [Accessed 13 May 2014]
2. Global Burden of Disease Mortality and Causes of Death Collaborators. Global, regional, and national age-specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease study 2013. Lancet 2015; 385: 117-171.
3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-115.
4. UNITAID. Hepatitis C medicines and technology landscape report. http:// unitaid.org/images/marketdynamics/publications/HCV-Meds-Landscape- Feb2015.pdf [Accessed 6 March 2015].
5. van de Ven N, Fortunak J, Simmons B, et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 2015; 61:1174-1182.
6. Zeuzem S, Wolfgang J, DushelkoGM, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases: Washington DC, USA 1-3 November 2013.
7. Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med 2014; 370:211-221.
8. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
9. Zarski JP, Strum N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study. J Hepatol 2012; 56:55-62.
10. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120.
11. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection, April 2014. http://www.who.int/hiv/pub/ hepatitis/hepatitis-c-guidelines/en/. [Accessed 10 October 2014]
12. Shivkumar S, Peeling R, Jafari Y, et al. Accuracy of rapid and point-of-care screening tests for hepatitis C. A systematic review and meta-analysis. Ann Intern Med 2012; 157:558-566.
13. Mullis CE, Laeyendecker O, Reynolds SJ, et al. High frequency of falsepositive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis 2013; 57:1747-1750.
14. Shivkumar S, Peeling R, Jafari Y, et al. Accuracy of rapid and point-of-care screening tests for hepatitis C. Ann Intern Med 2012; 157:558-566.
15. Smith BD, Teshale E, Jewett A, et al. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 2011; 53:780-786.
16. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase- to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726.
17. Johannessen A, LeMoine M. Is aspartate aminotransferase-to-platelet ratio index a reliable tool in human immunodeficiency virus patients in Africa? Liver International 16 February 2015 DOI: 10.1111/liv.12793.
18. Hill A, Saleem J, Cooke G et al.. Effects of sustained virological response on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34, 563 patients with hepatitis C infection. American Association for the Study of Liver Disease conference, Boston, USA, November 2014. [abstract].
19. EASL. EASL Clinical Practice Guidelines: 2013 revised version. Clinical practice guidelines to optimize the management of hepatitis C virus infection. http://www.easl.eu/-clinical-practice-guideline/issue-5-2013-revised-version- clinical-practice- guidelines-to-optimise-the-management-of-hepatitis-cvirus- infection. [Accessed 2 April 2014].
20. Gu S, Liu J, Zhang H, et al. Core antigen tests for hepatitis C virus: a metaanalysis. Mol Biol Rep 2012; 39:8197-8208.
21. Greenman J, Roberts T, Cohn J, Messac L. Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepat 2014; 22:353-361.
22. Tuaillon E, Mondain A, Meroueh F, et al. Dried blood spot for HCV serology and molecular testing. Hepatology 2010; 51:752-758.
23. UNITAID. 2014 hepatitis diagnostic technology landscape, 1st edition. http:// unitaid.org/images/marketdynamics/publications/UNITAID-HCV-Diagnosti c-Landscape-1st-edition.pdf [Accessed 6 March 2015].
24. Graham C, Swan T. A path to eradication of hepatitis C in low- and middleincome countries. Antiviral Res 2015; 119:89-96.